Sophia Genetics SA

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on August 25, 2026 for $8.68 per share.

Kathy L Hibbs, a Director of SOPHiA GENETICS SA, sold 6,250 shares of common stock on August 25, 2026 for $8.68 per share.

Manuela Valente, Chief People Officer of SOPHiA GENETICS SA, sold 10,000 shares of common stock on August 19, 2026 for $7.94 per share.

Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 20,000 shares of common stock on August 19, 2026.

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on August 12, 2026 for $7.52 per share.

Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 4,000 shares of common stock on August 13, 2026 for $7.52 per share.

Balderton Capital VI, S.L.P. has filed an Amendment No. 3 to its Schedule 13G, reporting beneficial ownership of 4.9% of Sophia Genetics SA's Ordinary Shares.

Akre Capital Management, LLC, along with Braddock Partners Offshore, LP and Braddock Capital Offshore, LLC, has disclosed a passive beneficial ownership of 5.6% in SOPHiA GENETICS SA, totaling 3,719,140 ordinary shares.